MET and gastric cancer: Correspondingly, MET gene amplification with consequent protein overexpression and constitutive kinase activation has been reported in 2-4% [67, 153] of advanced stage GC cases, amplifications of MET have been detected in 8% of CIN GC lesions, and MET mutations are present in approximately 3% of MSI subtype GCs [4].